MELLEVA 35 2mg / 0.035mg tablets medication leaflet

G03HB01 cyproterone + ethinyl estradiol • Genito urinary system and sex hormones | Antiandrogens | Antiandrogens and estrogens

The combination of cyproterone and ethinylestradiol is used for the treatment of severe acne, hirsutism, and other conditions caused by excess androgens in women. Cyproterone is an antiandrogen that reduces the effects of androgen hormones, while ethinylestradiol is an estrogen that regulates the menstrual cycle.

The medication is taken orally, as directed by a doctor, usually once daily at the same time each day. It is important for patients to follow the treatment regimen to achieve maximum benefits.

Patients should be aware of potential side effects, such as nausea, headaches, or mood changes. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, headaches, and breast tenderness. In rare cases, severe reactions such as venous thromboembolism or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about MELLEVA 35 2mg / 0.035mg

Substance: cyproterone + ethinyl estradiol

Date of last drug list: 01-01-2014

Commercial code: W52427001

Concentration: 2mg / 0.035mg

Pharmaceutical form: tablets

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).